This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Athauda, G. Articles by Bottaro, D. P. Search for Related Content PubMed PubMed Citation Articles by Athauda, G. Articles by Bottaro, D. P.

c-Met Ectodomain Shedding Rate Correlates with Malignant Potential

Authors' Affiliations: ¹ Urologic Oncology Branch, ² Laboratory of Molecular Pharmacology, and ³ Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland; ⁴ Department of Urology, Georgetown University School of Medicine, Washington, District of Columbia; and ⁵ Department of Cancer Biology, Amgen, Inc., Thousand Oaks, California

Requests for reprints: Donald P. Bottaro, Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Building 10, CRC 1 West Room 3961, 10 Center Drive MSC 1107, Bethesda, MD 20892-1107. Phone: 301-402-6499; Fax: 301-402-0922; E-mail: dbottaro{at}helix.nih.gov.

Purpose: Many proteins are proteolytically released from the cell surface by a process known as ectodomain shedding. Shedding occurs under normal physiologic conditions and can be increased in certain pathologies. Among the many receptors for which ectodomain shedding has been shown is c-Met, the hepatocyte growth factor (HGF) receptor tyrosine kinase. HGF stimulates mitogenesis, motogenesis, and morphogenesis in a variety of cellular targets during development, homeostasis, and tissue regeneration. Inappropriate HGF signaling resulting in unregulated cell proliferation, motility, and invasion occurs in several human malignancies. This can occur through paracrine signaling, autocrine loop formation, receptor mutation, gene amplification, or gene rearrangement, accompanied frequently with overexpression of ligand and/or receptor proteins. We hypothesized that c-Met overexpression in cancer might result in increased ectodomain shedding, and that its measure could be a useful biomarker of tumor progression.

Experimental Design: We developed a sensitive electrochemiluminescent immunoassay to quantitate c-Met protein in cell lysates, culture supernatants, and biological samples.

Results: A survey of cultured cell models of oncogenic transformation revealed significant direct correlations (P < 0.001, t test or ANOVA) between malignant potential and the rate of c-Met ectodomain shedding that was independent of steady-state receptor expression level. Moreover, weekly plasma and urine samples from mice harboring s.c. human tumor xenografts (n = 4 per group) displayed soluble human c-Met levels that were measurable before tumors became palpable and that correlated directly with tumor volume (R² > 0.92, linear regression).

Conclusions: For a variety of human cancers, c-Met ectodomain shedding may provide a reliable and practical indicator of malignant potential and overall tumor burden.

This article has been cited by other articles:

				A. L. Russo, K. Jedlicka, M. Wernick, D. McNally, M. Kirk, M. Sproull, S. Smith, U. Shankavaram, A. Kaushal, W. D. Figg, et al. Urine Analysis and Protein Networking Identify Met as a Marker of Metastatic Prostate Cancer Clin. Cancer Res., July 1, 2009; 15(13): 4292 - 4298. [Abstract] [Full Text] [PDF]

				S. Goldoni, A. Humphries, A. Nystrom, S. Sattar, R. T. Owens, D. J. McQuillan, K. Ireton, and R. V. Iozzo Decorin is a novel antagonistic ligand of the Met receptor J. Cell Biol., May 18, 2009; 185(4): 743 - 754. [Abstract] [Full Text] [PDF]